Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade

被引：2
|
作者：
Wu, Richard C. [1 ,2 ]
Luke, Jason J. [3 ,4 ]
机构：
[1] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH 43210 USA
[2] Div Med Oncol, Columbus, OH USA
[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[4] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA
来源：
CLINICAL CANCER RESEARCH | 2024年 / 30卷 / 01期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1158/1078-0432.CCR-23-2437
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this CCR Translations, we discuss the therapeutic potential of CD40 agonism, which stimulates antigen-presenting cells (APC) to activate effector T and NK cells. CD40 agonism may lead to development of an interferon-activated, T cell-inflamed tumor microenvironment and has the potential to facilitate long-term response with immune checkpoint blockade.
引用
收藏
页码：9 / 11
页数：3
相关论文
共 50 条
  • [21] Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
    Luuk van Hooren
    Alessandra Vaccaro
    Mohanraj Ramachandran
    Konstantinos Vazaios
    Sylwia Libard
    Tiarne van de Walle
    Maria Georganaki
    Hua Huang
    Ilkka Pietilä
    Joey Lau
    Maria H. Ulvmar
    Mikael C. I. Karlsson
    Maria Zetterling
    Sara M. Mangsbo
    Asgeir S. Jakola
    Thomas Olsson Bontell
    Anja Smits
    Magnus Essand
    Anna Dimberg
    Nature Communications, 12
  • [22] Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
    van Hooren, Luuk
    Vaccaro, Alessandra
    Ramachandran, Mohanraj
    Vazaios, Konstantinos
    Libard, Sylwia
    van de Walle, Tiarne
    Georganaki, Maria
    Huang, Hua
    Pietilae, Ilkka
    Lau, Joey
    Ulvmar, Maria H.
    Karlsson, Mikael C. I.
    Zetterling, Maria
    Mangsbo, Sara M.
    Jakola, Asgeir S.
    Bontell, Thomas Olsson
    Smits, Anja
    Essand, Magnus
    Dimberg, Anna
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [23] CD74 is a potential biomarker predicting the response to immune checkpoint blockade
    Shi, Wen-Qi
    Chen, Dan-Xun
    Du, Ze-Sen
    Liu, Chun-Peng
    Zhai, Tian-Tian
    Pan, Feng
    Chen, Hai-Lu
    Liao, Wei-Nan
    Wang, Shao-Hong
    Fu, Jun-Hui
    Qiu, Si-Qi
    Wu, Zhi-Yong
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [24] Dendritic Cells Enhance Immune Checkpoint Blockade Therapy
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (06) : 1176 - 1176
  • [25] Neoadjuvant CD40 Agonism Remodels the Tumor Immune Microenvironment in Locally Advanced Esophageal/Gastroesophageal Junction Cancer
    Soto, Maira
    Filbert, Erin L.
    Yang, Hai
    Starzinski, Stephanie
    Starzinski, Alec
    Gin, Marissa
    Chen, Brandon
    Le, Phi
    Li, Tony
    Bol, Brandon
    Cheung, Alexander
    Zhang, Li
    Hsu, Frank J.
    Ko, Andrew
    Fong, Lawrence
    Keenan, Bridget P.
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (01): : 200 - 212
  • [26] CD40 blockade shows promise in pSS trial
    Clarke J.
    Nature Reviews Rheumatology, 2020, 16 (3) : 126 - 126
  • [27] CD40 Expression in Fibrocytes Is Induced by TSH: Potential Synergistic Immune Activation
    Mester, Tuende
    Raychaudhuri, Nupur
    Gillespie, Erin F.
    Chen, Hong
    Smith, Terry J.
    Douglas, Raymond S.
    PLOS ONE, 2016, 11 (09):
  • [28] Immune dysfunction of uremic patients:: potential role for the soluble form of CD40
    Contin, C
    Couzi, L
    Moreau, JF
    Déchanet-Merville, J
    Merville, P
    NEPHROLOGIE, 2004, 25 (04): : 119 - 126
  • [29] Effects of CD40/CD154 blockade on allograft rejection
    Yuan, X
    Dong, VM
    Coito, AJ
    Waaga, A
    Salama, AD
    Benjamin, CD
    Sayegh, MH
    Chandraker, A
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (04) : A34 - A34
  • [30] Update on CD40 and CD154 blockade in transplant models
    Zhang, Tianshu
    Pierson, Richard N.
    Azimzadeh, Agnes M.
    IMMUNOTHERAPY, 2015, 7 (08) : 899 - 911
12345